Niels Teich

• co-owner of practice at Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten

Background The prospective RUN-CD registry investigates the effectiveness of ustekinumab (UST) and other biologics in Crohn’s disease (CD) across Germany. Based on data from the registry, this study presents the maintenance phase results of a 12-month real-world-evidence (RWE) comparison of CD patients initiating new biologic therapies with UST or...

Introduction: Long-term sequelae following acute SARS-CoV-2 infection appear to be common in patients with inflammatory bowel diseases (IBDs). Methods: We examined the frequency and characteristics of post-COVID-symptoms in patients with IBD (IBD-COVID), comparing them to two control cohorts: infected household members of the IBD-COVID patients...

Background Data regarding effectiveness and safety of JAK inhibitors and S1P receptor modulators in chronic antibiotic refractory pouchitis (CARP) are lacking. This ECCO-CONFER project collected cases of CARP treated with JAK inhibitors or S1P receptor modulators. Methods This retrospective multicentre study collected cases across Europe through t...

Background Integrating systematic monitoring of patient-reported outcomes (PROs) with clinical information may enhance disease management and improve patient outcomes. Vedolizumab (VDZ) is approved for treating patients with ulcerative colitis (UC) and Crohn’s disease (CD). The German, multicentre, prospective, non-interventional LISTEN II study ev...

Background Microscopic colitis (MC) is a chronic inflammatory condition of the colon, resulting in an impaired quality of life due to debilitating watery diarrhea. First-line therapy consists of budesonide, though a subset of patients is refractory or becomes budesonide- dependent. Evidence for the efficacy of biologicals or small molecules in MC i...

Background The number of advanced therapies (ADT) approved for the treatment (Tx) of inflammatory bowel disease (IBD) in is increasing, however, yet no guidance on optimal sequencing of treatments is available in Germany (and elsewhere). This study aims to investigate applied Tx sequences of ADT in claims data based on real-world setting across Ger...

Background and Aims Data regarding effectiveness and safety of JAK inhibitors and S1P receptor modulators in antibiotic refractory chronic pouchitis (CARP) are lacking. Methods This ECCO-CONFER project retrospectively collected JAK inhibitors or S1P receptor modulators treatments for CARP with at least 3-months follow up. The outcomes included cor...

Background: The aim of this observational, real-world evidence, modified intention-to-treat (mITT) study based on prospectively collected data from the VEDOIBD registry was to compare the effectiveness of vedolizumab (VEDO) vs antitumor necrosis factor (anti-TNF) in biologic-naïve Crohn's disease (CD) patients. Methods: Between 2017 and 2020, 55...

Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory disease affecting skin that bears apocrine glands and is characterised by painful, deep-seated, inflamed lesions. Treatment includes antibiotics, steroids, surgery, and adalimumab as the only approved biological agent. An association between inflammatory bowel disease (IB...

The coronavirus disease 2019 (COVID-19) pandemic continues to impact the lives of patients with inflammatory bowel disease (IBD). Extensive investigations over the past 3 years have shown that the vast majority of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infections and COVID-19 diseases in IBD patients are mild. The disease...

Background Vedolizumab (VDZ) is a gut-selective anti-lymphocyte trafficking integrin antibody and is approved for treating patients with moderately to severely active UC (ulcerative colitis) and CD (Crohn’s disease) intravenously (IV) or subcutaneously (SC). The LISTEN II study aims to determine patient characteristics and effectiveness in patients...

Background Within the framework of the prospective real-world RUN-CD registry on the effectiveness and safety of ustekinumab (UST) in Crohn’s disease (CD), a total of 901 CD-patients undergoing a newly initiated biologics therapy were enrolled in 44 IBD-experienced centers from all over Germany between 2017-2020 with a follow-up of 3 years. Here, t...

Background Since April 2020, vedolizumab (VEDO) has been available for use in IBD in intravenous (iv) and subcutaneous (sc) formulations. Due to limited data on real-world use and effectiveness, the objectives of this real-world evidence (RWE), observational, prospective study are to observe (1) the time point of conversion to VEDO sc, (2) the 6-mo...

Background To gain insight into vedolizumab (VEDO) use as a first-line biologic in Crohn′s disease (CD), this comparative, two-arm prospective real-world-evidence (RWE) study with propensity score (PS) adjustment aimed to assess, within the maintenance phase, the 2-year comparative effectiveness and persistence of VEDO vs anti-TNF therapy in biolog...

Background: In addition to randomized controlled trials (RCTs), real-world studies on the effectiveness of ustekinumab (UST) in Crohn's disease (CD) are required inasmuch as RCTs are usually confined to selected patients, which may not represent everyday clinical practice. Within the framework of the prospective real-world RUN-CD registry, a total...

Background: The therapeutic goal of clinical remission in patients with moderate to severe ulcerative colitis (UC) is achieved after biological therapy only in 16% to 39%. Individualization of therapeutic intervention would benefit from prediction of early response. Study objective: The primary objective of our study was to assess golimumab (GLM...

Purpose Despite the wide range of medical and interventional therapy options available, some patients with Crohn’s disease (CD) need an ileostomy or colostomy. The aim of this study was to identify clinical, surgical and drug-related predictors of successful stoma reversal in CD patients. Methods A retrospective medical record analysis of surgical...

Background and study aims The success of colonoscopy is mainly dependent on the effectiveness of prior bowel preparation (BP). Patients often consider BP to be the most burdensome part of colonoscopy, which might be a main barrier to the procedure. The aim of this study was to evaluate safety and effectiveness of colonic irrigation with a new colon...

Background Hereditary colorectal cancer syndromes (HCCS) are rare polyposis or nonpolyposis syndromes with a higher risk of developing colorectal cancer (CRC). Coexisting inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), with HCCS is exceedingly rare and presumably increases the risk of early-onset CRC....

Introduction: Fatigue is a common symptom in patients with inflammatory bowel diseases (IBD). To date, there is no instrument to assess IBD-specific fatigue in German. The aim of this study was to translate the IBD Fatigue (IBD-F) scale and to test its psychometric properties in a German IBD population. Methods: After completing the translation...

Aims i) To evaluate the evolution of pregnancies and offspring after inflammatory bowel disease (IBD) surgery during pregnancy; and ii) to describe the indications, the surgical techniques, and the frequency of caesarean section concomitant to surgery. Methods Patients operated on due to IBD during pregnancy after 1998 were included. Participating...

Zusammenfassung Die COVID-19-Pandemie beeinflusst das Leben von Patient*innen mit chronisch-entzündlichen Darmerkrankungen (CED) in erheblicher Weise. Betroffene und Angehörige haben zahlreiche Fragen zum Erkrankungsrisiko, zum Verlauf einer möglichen SARS-CoV-2-Infektion oder auch zum Einfluss der CED-spezifischen Therapie. Auch bestehen bei viele...

Background To gain insight into vedolizumab (VDZ) use as a first-line biologic in Crohn′s Disease (CD), this real-world study aimed to assess, within the maintenance phase, the 1-year comparative effectiveness and persistence of VDZ vs anti-TNF therapy in biologic-naïve CD-patients. Methods Between 2017–2020, 1200 consecutively enrolled biologic-n...

Background Observational real world studies are required in addition to RCTs which typically represent selected patients not reflecting everyday clinical practice. Between 2017–2020 patients with Crohn’s disease (CD) receiving a newly initiated biologics therapy were consecutively enrolled into the prospective, observational RUN-CD registry from 44...

Background Data on the outcomes of surgery due to IBD in pregnant patients is scarce, and primarily dates back more than 3 decades ago. Primary aim: to evaluate the evolution of pregnancies and offspring after surgery due to IBD. Secondary aims: to describe the indications for surgery, the surgical techniques used, and the frequency of caesarean se...

Background Hereditary colorectal cancer syndromes (HCCS) are rare polyposis or nonpolyposis syndromes with a higher risk of developing colorectal cancer (CRC). Coexisting inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), with HCCS is exceedingly rare and presumably increases the risk of early-onset colore...

Background Vaccination against SARS-CoV-2 is a promising strategy to protect immunocompromised IBD patients from a severe course of COVID-19. As these patients were excluded from initial clinical vaccination trials, patients frequently express concerns regarding the safety of these vaccines, especially whether vaccination might trigger IBD flares (...

Background Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) have rarely been reported in association with inflammatory bowel diseases (IBDs). Methods An ECCO COllaborative Network For Exceptionally Rare case reports project (ECCO-CONFER) collecting cases of GEP-NENs diagnosed in patients with IBD. Results GEP-NEN was diagnosed in 100 IB...

Background There is a small but measurable increased risk of lymphoma in inflammatory bowel disease (IBD), with a suggestion that primary intestinal lymphoma in IBD is associated with inflamed tissue and immunosuppressant use, mainly thiopurines. Methods This multicentre case series was supported by the European Crohn’s and Colitis Organisation (E...

Background Several patient reported outcomes (PRO) have been established and are widely used in the assessment of patients with inflammatory bowel disease (IBD). However, it has never been investigated which PRO items are experienced by and are considered most relevant for IBD patients. Methods A review of IBD-related disease scores by a steering...

Introduction: The influence of a SARS-CoV-2 infection on inflammatory bowel disease (IBD) has not yet been well characterized and it is unclear whether this requires an adaptation of the immunosuppressive therapy. Methods: A national register was established for the retrospective documentation of clinical parameters and changes in immunosuppress...

Background Prospective, observational real world studies on the effectiveness and safety of ustekinumab (UST) in Crohn’s disease (CD) are required in addition to RCTs, usually confined to selected patients, which may not represent special treatment patterns and everyday clinical practice. The aim of the present 3-year RUN-CD study was to investigat...

Background Neuroendocrine Neoplasms (NENs) are a heterogeneous group of tumours deriving from the diffuse endocrine system. NENs may occur almost everywhere in the body but are most common in the gastrointestinal tract, the pancreas, and the lungs, with gastroenteropancreatic (GEP) tumours representing 70% of all NENs. GEP-NENs have rarely been rep...

Introduction: Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is a challenging operation. Especially the mobilization of the pouch into the pelvis can be complex. Adequate perfusion of the pouch is required for optimal healing and functioning. Methods: With hyperspectral imaging (HSI) wavelengths between 500 and 1,000 nm can...

Abstract Background Ulcerative colitis (UC) is a chronic inflammatory bowel disease with recurrent episodes of debilitating symptoms negatively affecting work productivity and health-related quality of life (HRQoL). The use of biologics in UC treatment improves work and HRQoL but prospective long-term data concerning the treatment with TNFα inhibit...

Background This analysis of the Observational Postmarketing Ulcerative Colitis Study examined incidence rates of colectomy in patients with ulcerative colitis who received originator infliximab (IFX) or conventional therapies (ConvRx) as per their treating physician. Methods Cox proportional hazards models compared time to colectomy for both treat...

Objective: Knowledge about SARS-CoV2 and coronavirus disease 2019 (COVID-19) is growing fast. Massive changes in the health care system imposed by the COVID-19 pandemic clearly impact the overall quality of medical care. In this survey, we aim to explore experiences and concerns of patients with inflammatory bowel disease (IBD) regarding the curre...

Introduction: Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn's disease (CD), but whether this benefit results in reduced hospitalization rates and therefore may improve patients' quality of life in an economically sensible way is conflicting so far. Methods: We conducted a nonint...

Background Physicians can improve their relationships with patients by understanding and meeting patients’ treatment targets, leading to higher adherence to therapy and improved disease prognosis. In the current study, we performed a questionnaire-based survey to further understand treatment targets in patients with inflammatory bowel disease (IBD)...

Patienten mit chronisch-entzündlichen Darmerkrankungen (CED) sind infolge ihrer Grundkrankheit, aber auch durch die häufig notwendige immunsuppressive Therapie gefährdet, an einer impfpräventablen Infektionskrankheit zu erkranken. Mehrere Erhebungen des Impfstatus von CED-Patienten mit CED ergaben jedoch erhebliche Abweichungen von den offiziellen...

Background: The hygiene hypothesis suggests that a reduction in microbial exposure contributes to an impaired immune response later in life and increases the incidence of immune-mediated diseases such as inflammatory bowel diseases (IBD). Thumb sucking and nail biting are two early habits that modulate the oral microbiota composition and antigen l...

Zusammenfassung Die COVID-19-Pandemie ist ein weltweiter Ausbruch von neu aufgetretenen Infektionen mit dem SARS-CoV-2-Virus, von denen weltweit derzeit mehr als 10.670.000 Menschen erkrankt sind bzw. waren. In Deutschland leiden ca. 450.000 Patienten an einer chronisch entzündlichen Darmerkrankung; diese Patienten benötigen in der Regel eine konti...

Background: The coronavirus disease 2019 (COVID-19) pandemic is affecting lives worldwide. The influence of inflammatory bowel disease (IBD) medication and IBD itself on COVID-19 is controversial. Additionally, IBD focused guidance is scarce. Objective: To determine COVID-19 prevalence/exposure, perception and information sources, medication com...

Background: The introduction of biologics has revolutionized the management of the chronic inflammatory bowel disease, ulcerative colitis (UC), with many patients experiencing significant improvements not only in their symptoms but in other outcomes relevant to individuals and society as a whole. In Germany, there are no prospective data > 3 mo th...

Background There is a small but measurable increased risk of lymphoma in inflammatory bowel disease (IBD). Evidence coming from case reports and small case series of primary intestinal lymphoma in IBD suggest an association with inflamed tissue and immunosuppressant use, mainly thiopurines. Methods This was a multicentre case series supported by t...

Background and aims: Crohn's disease (CD) can involve any part of the gastrointestinal tract. We aimed to characterize clinical, endoscopic, histologic features and treatment outcomes of CD patients with oesophageal involvement. Methods: We collected cases through a retrospective multicentre European Crohn's and Colitis Organisation CONFER [COll...

Purpose The aim of our study was to identify clinical parameters in recently diagnosed Crohn’s disease (CD) patients for prediction of their disease course. Methods EPIC (Early Predictive parameters of Immunosuppressive therapy in Crohn’s disease) is a prospective, observational study in 341 patients with a recent CD diagnosis (≤ 6 months), and na...

Background and aims This study examined differences in personality, psychological distress, and stress coping in inflammatory bowel disease (IBD) depending on type of disease and disease activity. We compared patients suffering from Crohn’s disease (CD) and ulcerative colitis (UC) with controls. While the literature is replete with distinctive feat...

Purpose Cytomegalovirus (CMV) infection has been found to be associated with a reactivation of ulcerative colitis (UC) and with an impaired response to medical therapy. In the past, only limited data were available on the long-term outcome for UC patients with positive tissue CMV-PCR in the colonic mucosa. Methods Between January 2010 and April 20...

Background and aims: The Observational Postmarketing Ulcerative colitis Study (OPUS) was conducted to obtain the first long-term (5 years) safety data assessing treatment with originator infliximab versus conventional therapies in patients with ulcerative colitis (UC) in real-world clinical practice. Methods: The OPUS registry was a prospective,...

Background RUN-CD study is an investigator initiated, ongoing, non-interventional trial on biologics in Crohn′s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction and maintenance therapy of biologics, especially of UST. Aim of this analysis was to compare steroid-free remission rates and QoL in CD-patien...

Background Crohn’s disease (CD) can involve any part of the gastrointestinal tract. We aimed to characterise clinical, endoscopic, histological features and treatment outcomes of CD patients with oesophageal involvement. Methods This was a European Crohn’s and Colitis Organization (ECCO) retrospective observational study performed as part of CONFE...

Background Prospective data evaluating work productivity and activity in real-world practice are available in patients with moderate to severe ulcerative colitis (UC) treated with Golimumab (GLM) are rare. The aim of this study was to assess the change of work productivity, activity and quality of life (QoL) in UC patients treated with GLM for 2 ye...

This guideline provides evidence-based key recommendations for diagnosis and treatment of ulcerative colitis and upgrades the 2011 version. The guideline was developed by an interdisciplinary team of gastroenterologists, surgeons, pathologists, nutrition experts, and patient support groups under the auspice of the German Society for Gastroenterolog...

Objective Coagulation factor XIII plays a key role in fibrin clot stabilization and epithelial healing. Under chronic inflammatory conditions involving bleeding and an activation of the coagulation cascade, the FXIIIa inversely correlate with disease activity. We assumed that FXIIIa could be a predictor of severity in patients with ulcerative colit...

Zusammenfassung Patienten mit chronisch-entzündlichen Darmerkrankungen (CED) haben ein deutlich erhöhtes Risiko für Clostridioides [Clostridium] difficile Infektionen (CDI). Eine CDI kann ihrerseits die Aktivität der luminalen Entzündung erhöhen. Daher ist eine rasche Diagnostik und Therapie erforderlich. Viele Diagnose- und Behandlungsstudien zu P...

Zusammenfassung Die neue S3-Leitlinie Colitis stellt aktuelle und evidenzbasierte Empfehlungen zur Behandlung der Colitis ulcerosa zur Verfügung. Sie ersetzt damit die Vorläuferversion von 2011. Neben den neuesten Erkenntnissen zu Diagnostik und Therapie werden insbesondere infektiologische Probleme, chirurgische und Ernährungsmaßnahmen aufgegriffe...

Significant increases in Crohn’s disease incidence have been noticed in recent decades. Therefore it gets more important to increase practical knowledge, present therapy innovations and draw attention to the need for vaccinations of immunosuppressed IBD patients as well as useful supportive therapy options. Eine deutliche Inzidenzsteigerung in den...

en Linked Content This article is linked to Wilson et al papers. To view these articles visit https://doi.org/10.1111/apt.14483 and https://doi.org/10.1111/apt.14562.

Background: Intra-abdominal abscesses (IAA) are common life threatening complications in patients with Crohn's disease (CD). In addition to interventional drainage and surgical therapy, empirical antibiotic therapy represents a corner stone of treatment but contemporary data on microbial spectra and antimicrobial resistance are scarce. Methods:...

Background The Observational Postmarketing Ulcerative colitis Study (OPUS) registry was conducted to collect long-term (5 years) real-world clinical practice safety data in patients with moderate to severe ulcerative colitis (UC) treated with originator infliximab (IFX) and to compare this safety profile to that of UC patients treated with conventi...

Background No prospective data evaluating work productivity and activity in real-world practice are available in patients with moderate to severe ulcerative colitis (UC) treated with Golimumab (GLM) for more than 3 months. The aim of this study is to assess the change of work productivity, activity and quality of life (QoL) in UC patients treated w...

Background and study aims Patients with malignant tumors of the upper gastrointestinal tract are at risk of weight loss. Early supportive nutrition therapy is therefore recommended and usually requires placement of a percutaneous endoscopic gastrostomy (PEG). The aim of this study was to compare adverse events and usage characteristics of the direc...

Background: The most common complication after ileal pouch anal anastomosis in up to 50% of patients is an acute pouchitis. The majority of patients respond to antibiotic treatment. However, 10%-15% develops chronic antibiotic-dependent or refractory pouchitis which is usually hard to treat. Aim: To evaluate the effectiveness of vedolizumab in p...